Loading clinical trials...
Loading clinical trials...
A Phase 1/2a Open Label, Multicenter Study to Access the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients With Advanced Solid Tumors
Conditions
Interventions
14 mg AFM24
40 mg AFM24
+5 more
Locations
13
United States
University of Southern California
Los Angeles, California, United States
Dana Faber Cancer Institute
Boston, Massachusetts, United States
Nordwest Hospital GmbH
Frankfurt am Main, Hesse, Germany
University Duisburg-Essen, University Hospital Essen
Essen, Germany
University Hospital Hamburg-Eppendorf
Hamburg, Germany
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Start Date
April 7, 2020
Primary Completion Date
July 12, 2023
Completion Date
June 24, 2024
Last Updated
July 17, 2025
NCT05720117
NCT06898450
NCT05098132
NCT05719558
NCT07477743
NCT04585750
Lead Sponsor
Affimed GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions